KBC Group’s ImmunityBio IBRX Stock Holding History

KBC Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$97K	Hold	10,307	–	–	﹤0.01%	1407
2026 Q2	$90K	Hold	10,307	–	–	﹤0.01%	1481
2026 Q1	$79K	Buy	+10,307	New	+$70.6K	﹤0.01%	1459

Other funds holding IBRX

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Vestor Capital Chicago, Illinois $1.59B AUM 24.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Allen Holding New York $1.15B AUM 24.01% 1-Year Est. Return

Kercheville Advisors San Antonio, Texas $361M AUM 57.53% 1-Year Est. Return

D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return

Sheets Smith Wealth Management Winston-Salem, North Carolina $958M AUM 21.88% 1-Year Est. Return

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Plancorp LLC Saint Louis, Missouri $4.4B AUM 16.7% 1-Year Est. Return

KBC Group's IBRX Position: Q3 2026 in Review

KBC Group held its ImmunityBio (IBRX) position steady in Q3 2026 at 10,307 shares worth $97K. The position accounts for ﹤0.01% of the portfolio, ranked #1407.

KBC Group first reported a position in IBRX in Q1 2026 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

KBC Group held 10,307 shares of ImmunityBio worth $97K as of Q3 2026.
KBC Group left its ImmunityBio share count unchanged in Q3 2026.
ImmunityBio made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1407 holding.
KBC Group first reported a position in ImmunityBio in Q1 2026 and has held it in 3 quarters since.
147 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.